EGFR Biomarkers
News and reporting on EGFR biomarkers.
Black Diamond Therapeutics Restructures Workforce, Deprioritizes RAF Program
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.
Pierre Fabre, Scorpion Therapeutics Begin Phase I/II Trial in 'Double-Mutant' NSCLC Patients
The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.
Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.
AstraZeneca Nabs FDA Approval for Tagrisso in Stage III, Unresectable EGFR-Mutated NSCLC
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
Kairos Pharma, PreCheck Health Services to Develop CDx for Prostate, Lung Cancer Drug
PreCheck will help the biopharma firm confirm and validate biomarkers previously identified in early-phase trials for companion diagnostic use.
May 16, 2024